<DOC>
	<DOCNO>NCT03092934</DOCNO>
	<brief_summary>This two-part study consist Phase 1 dose escalation study participant locally advance metastatic solid tumor , Phase 2 portion 3 cohort either Small Cell Lung Cancer , Breast Cancer and/or one solid tumor type</brief_summary>
	<brief_title>A Study AK-01 Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have receive least 1 4 prior systemic therapy Have adequate organ function Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Have estimate life expectancy great equal ( â‰¥ ) 12 week Have fully recover radiation therapy surgery , recover acute adverse effect cancer therapy Have discontinue chemotherapy , investigational therapy , molecularlytargeted therapy , cancerrelated hormonal therapy least 14 day prior , biologic immunotherapeutic therapy least 21 day prior , mitomycinC nitrosoureas least 6 week prior Female participant reproductive potential agree use 2 form highly effective contraception study follow 3 month Male participant must use barrier method contraception study follow 3 month Phase 1 Have evidence solid tumor locally advance and/or metastatic ( exclude primary brain tumor ) Phase 2 Have disease measurable Response Evaluation Criteria Solid Tumors ( RECIST ) v.1.1 Have evidence solid tumor locally advance and/or metastatic , : Small Cell Lung Cancer ( SCLC ) , must fail platinumcontaining therapy Breast Cancer , Estrogen Receptor positive and/or Progesterone Receptor positive , Human Epidermal Growth Factor Receptor 2 ( HER2 ) negative , must fail hormone therapy Cyclindependent kinase 4/6 ( CDK4/6 ) inhibitor Have solid tumor type approve sponsor Have symptomatic central nervous system ( CNS ) metastasis ( unless asymptomatic current receiving corticosteroid ) primary tumor CNS Have medical condition precludes participation ( swallow disorder , organ transplant , pregnant nursing , HIV , active Hepatitis B C , cardiac disease , history major surgery upper gastrointestinal ( GI ) tract GI disease , hypokalemia , hypomagnesaemia hypocalcaemia control )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Small Cell Lung Carcinoma</keyword>
</DOC>